Business Context and Reporting Period
This Form 8-K was filed by Tempest Therapeutics, Inc. on June 5, 2025. The report details a significant management transition involving the Company's top executives in support of a strategic process to explore alternatives and extend capital resources, as previously announced on April 18, 2025.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and employment status changes.
Material Changes
- Executive Transition: On June 5, 2025, CEO Stephen Brady, Executive Vice President and CMO Samuel Whiting, and CFO Nicholas Maestas transitioned from full-time employment to one-year consulting agreements.
- Continued Roles: Despite the transition, Mr. Brady remains the principal executive officer and a board director, while Mr. Maestas remains the principal financial officer.
- Compensation Structure: The executives will now receive hourly compensation under the new consulting agreements.
- Equity Acceleration: All outstanding equity awards for the three executives were fully accelerated, becoming vested and exercisable as of June 5, 2025.
- Exercise Period: An extended post-transition exercise period was granted, lasting until the earlier of a Change of Control transaction or 180 days after separation from service.
Guidance, Outlook, and Risks
The Company is actively exploring a full range of strategic alternatives to extend its capital resources. The transition of executives to consulting roles is a direct measure to support these efforts. The filing notes that severance benefits are contingent upon the executives signing a general release of claims. There were no reported disagreements between the executives and the Company. Full text of the Consulting and Separation Agreements will be filed as exhibits to the upcoming Form 10-Q for the quarter ended June 30, 2025.
Investor Verification Checklist
- Verify the specific hourly compensation rates in the Consulting Agreements once filed as exhibits to the Form 10-Q.
- Confirm the total value of the accelerated equity awards for Brady, Whiting, and Maestas.
- Monitor the progress of the strategic alternatives process mentioned in the April 18, 2025 announcement.
- Review the upcoming Form 10-Q for any impact of the executive transition on the Company's cash burn rate and liquidity.